Point72 Asset Management L.P. raised its stake in Axovant Sciences Ltd. (NYSE:AXON) by 1,718.3% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 209,100 shares of the biotechnology company’s stock after buying an additional 197,600 shares during the period. Point72 Asset Management L.P. owned approximately 0.21% of Axovant Sciences worth $3,124,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Bank of America Corp DE raised its stake in Axovant Sciences by 38.9% in the first quarter. Bank of America Corp DE now owns 7,396 shares of the biotechnology company’s stock valued at $111,000 after buying an additional 2,072 shares during the last quarter. AQR Capital Management LLC acquired a new position in shares of Axovant Sciences during the fourth quarter valued at approximately $139,000. Oppenheimer & Co. Inc. acquired a new position in shares of Axovant Sciences during the first quarter valued at approximately $219,000. American International Group Inc. increased its position in shares of Axovant Sciences by 7.1% in the first quarter. American International Group Inc. now owns 15,052 shares of the biotechnology company’s stock valued at $225,000 after buying an additional 998 shares during the period. Finally, Wells Fargo & Company MN increased its position in shares of Axovant Sciences by 34.3% in the first quarter. Wells Fargo & Company MN now owns 22,435 shares of the biotechnology company’s stock valued at $335,000 after buying an additional 5,733 shares during the period. Institutional investors and hedge funds own 94.44% of the company’s stock.

Shares of Axovant Sciences Ltd. (NYSE AXON) traded down 0.86% during midday trading on Thursday, reaching $23.08. The company had a trading volume of 359,763 shares. Axovant Sciences Ltd. has a 52 week low of $11.01 and a 52 week high of $26.49. The company’s 50 day moving average price is $22.85 and its 200-day moving average price is $18.65. The company’s market capitalization is $2.48 billion.

Axovant Sciences (NYSE:AXON) last released its quarterly earnings data on Tuesday, June 13th. The biotechnology company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.51) by $0.02. On average, equities research analysts predict that Axovant Sciences Ltd. will post ($2.20) earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This report was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another publication, it was stolen and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this report can be read at https://www.thecerbatgem.com/2017/08/03/point72-asset-management-l-p-has-3-12-million-position-in-axovant-sciences-ltd-nyseaxon-updated-updated-updated.html.

Several equities analysts have commented on AXON shares. Piper Jaffray Companies reaffirmed an “overweight” rating and issued a $32.00 price objective on shares of Axovant Sciences in a research report on Wednesday, April 12th. Oppenheimer Holdings, Inc. reaffirmed an “outperform” rating and issued a $26.00 price objective (up previously from $20.00) on shares of Axovant Sciences in a research report on Friday, April 14th. Jefferies Group LLC reissued a “buy” rating and set a $31.00 price target on shares of Axovant Sciences in a research report on Tuesday, April 18th. CIBC increased their price target on Axovant Sciences from $30.00 to $33.00 and gave the stock a “neutral” rating in a research report on Tuesday, April 18th. Finally, Cowen and Company reissued an “outperform” rating and set a $30.00 price target (up previously from $22.00) on shares of Axovant Sciences in a research report on Tuesday, June 13th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and nine have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $28.50.

About Axovant Sciences

Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.

Institutional Ownership by Quarter for Axovant Sciences (NYSE:AXON)

Receive News & Stock Ratings for Axovant Sciences Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences Ltd. and related stocks with our FREE daily email newsletter.